Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Ophthalmology

Research, Clinical Trials, & Future Therapies

At a Glance

While there is no cure for Stargardt disease, research is rapidly advancing. Promising therapies in clinical trials include oral medications to slow toxic retinal buildup, targeted gene therapies for ABCA4 mutations, and stem cell treatments aiming to replace damaged eye cells.

We are currently in a “golden age” of research for Stargardt disease. While there is not yet a cure, several promising therapies are in the final stages of human testing. These treatments target the disease from different angles, from cleaning up the recycling system to replacing damaged cells [1][2].

Oral Medications: Slowing the Buildup

These are daily pills designed to prevent the production of toxic waste in the eye. They are currently the furthest along in the clinical trial process.

  • ALK-001 (Gildeuretinol): This is a modified, “deuterated” form of Vitamin A. It works like normal Vitamin A, but it has stronger chemical bonds that make it harder for the molecules to clump together into toxic waste [3][1]. In the TEASE clinical trials, this drug has shown promise in slowing the growth of macular atrophy over a two-year period [4][5].
  • Tinlarebant (LBS-008): Instead of modifying Vitamin A, this drug limits how much Vitamin A reaches the eye in the first place. It works by blocking a transport protein called RBP4 [6]. By lowering the “fuel” available for the visual cycle, it aims to reduce the formation of toxic byproducts [7][8].

Gene Therapy: Fixing the Source

Gene therapy aims to deliver a “healthy” version of the ABCA4 gene directly into the retina to take over for the broken one.

  • The “Big Gene” Challenge: The ABCA4 gene is very large—too large to fit into the standard “delivery trucks” (AAV vectors) used for other diseases [9][10].
  • Novel Solutions: Researchers are testing “Dual-AAV” systems, where the gene is split into two halves and then “zips” back together once inside the eye [11][12]. Other trials, like the STELLAR study, use RNA-based technology to “patch” the gene’s instructions instead of replacing the whole gene [T-43ZE6XXB].
  • Highly Specific: It is important to know that many gene and RNA therapies are highly specific to the exact genetic mutation a patient has. They may only work for a subset of the Stargardt population.

Stem Cell Therapy: Replacing What is Lost

While gene and drug therapies aim to save existing cells, stem cell therapy aims to replace the cells that have already died.

  • RPE Replacement: Early trials have shown that injecting healthy, lab-grown support cells (Retinal Pigment Epithelium) into the eye is safe and may help support the remaining light-sensing cells [13][14].
  • Future Goal: The long-term goal is to replace the photoreceptors themselves, though this remains in earlier stages of research compared to RPE replacement [15].

The Importance of Genetic Diagnosis

For almost every clinical trial today, a confirmed genetic diagnosis is a mandatory requirement [16][17].

  1. Precision Medicine: Many new treatments only work for specific “spelling errors” (mutations). For example, some trials only accept patients with certain types of “splicing” mutations [18].
  2. Accuracy: Researchers need to be 100% sure the vision loss is caused by ABCA4 and not a “look-alike” condition, so the trial results are accurate [19].

Current Clinical Trial Landscape & Registries

Several major trials are currently recruiting participants:

  • Phase 3 (Final Stage): ALK-001 and Tinlarebant (DRAGON study) are evaluating efficacy in large groups of patients [T-8FMMPXJO][2].
  • Gene Therapy: Trials like CELESTE are testing single-injection genetic treatments [T-13KAXRWJ].
  • Repurposed Drugs: The National Eye Institute is testing whether common medications like metformin might help protect the retina [T-D1K3V012].

To find a trial that fits your specific profile, you can visit ClinicalTrials.gov or explore resources provided by organizations like the Foundation Fighting Blindness (FFB). It is highly recommended to join a registry like the My Retina Tracker Registry through the FFB, which securely stores your genetic data and alerts you when a research study matches your specific mutations [T-43H2FAXN].

Common questions in this guide

Why is a genetic diagnosis required for Stargardt disease clinical trials?
Researchers need a confirmed genetic diagnosis to ensure your vision loss is definitively caused by ABCA4 mutations. Many new therapies are highly specific and only target certain genetic 'spelling errors' or splicing mutations.
What oral medications are being tested for Stargardt disease?
Researchers are testing daily pills like ALK-001, which is a modified Vitamin A, and Tinlarebant. These medications aim to slow down vision loss by preventing the buildup of toxic waste in the retina.
How does gene therapy for Stargardt disease work?
Gene therapy aims to deliver a healthy ABCA4 gene or a targeted RNA patch directly to the eye. While it is not yet a cure, clinical trials are evaluating if this approach can successfully take over for the broken gene and stop disease progression.
How can I find a clinical trial for Stargardt disease?
You can find recruiting trials on ClinicalTrials.gov or through the Foundation Fighting Blindness. Joining a patient registry like My Retina Tracker can also help researchers contact you directly when a trial matches your specific genetic profile.
What is the difference between gene therapy and stem cell therapy for Stargardt?
Gene therapy aims to fix the underlying genetic mutation to save your existing retinal cells. Stem cell therapy is designed to replace cells that have already died, such as the retinal pigment epithelium, to support your remaining vision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my genetic profile a match for any specific gene therapy or RNA-splicing trials currently recruiting?
  2. 2.How does the mechanism of ALK-001 (deuterated vitamin A) differ from the 'eye health' vitamins I've been told to avoid?
  3. 3.Are there any 'natural history' studies I should join now to be better prepared for future interventional trials?
  4. 4.What are the specific risks and potential benefits of subretinal surgery versus taking an oral medication like Tinlarebant?
  5. 5.How do you quantify my 'atrophy growth rate,' and is it slow or fast enough to qualify for current Phase 3 studies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model.

    Zhang D, Robinson K, Washington I

    Translational vision science & technology 2021; (10(14)):8 doi:10.1167/tvst.10.14.8.

    PMID: 34878528
  2. 2

    Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape.

    Dayma K, Rajanala K, Upadhyay A

    International journal of molecular sciences 2025; (26(14)) doi:10.3390/ijms26147006.

    PMID: 40725253
  3. 3

    Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies?

    Saad L, Washington I

    Advances in experimental medicine and biology 2016; (854()):355-61 doi:10.1007/978-3-319-17121-0_47.

    PMID: 26427432
  4. 4

    Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease.

    Wang L, Shah SM, Mangwani-Mordani S, Gregori NZ

    Journal of clinical medicine 2023; (12(19)) doi:10.3390/jcm12196229.

    PMID: 37834872
  5. 5

    Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease.

    Barthelemy N, Lee W, Gregori NZ, et al.

    Current opinion in ophthalmology 2026; (37(3)):205-214 doi:10.1097/ICU.0000000000001213.

    PMID: 41861379
  6. 6

    [New possibilities in the treatment of Stargardt disease].

    Zhorzholadze NV, Sheremet NL, Tanas AS, Strelnikov VV

    Vestnik oftalmologii 2020; (136(4. Vyp. 2)):333-343 doi:10.17116/oftalma2020136042333.

    PMID: 32880159
  7. 7

    Mechanisms of Feedback Regulation of Vitamin A Metabolism.

    O'Connor C, Varshosaz P, Moise AR

    Nutrients 2022; (14(6)) doi:10.3390/nu14061312.

    PMID: 35334970
  8. 8

    Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development.

    Kim N, Priefer R

    European journal of medicinal chemistry 2021; (226()):113856 doi:10.1016/j.ejmech.2021.113856.

    PMID: 34547506
  9. 9

    Stargardt Disease: Gene Therapy Strategies for ABCA4.

    Ku CA, Yang P

    International ophthalmology clinics 2021; (61(4)):157-165 doi:10.1097/IIO.0000000000000375.

    PMID: 34584053
  10. 10

    An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 Mice.

    McClements ME, Barnard AR, Singh MS, et al.

    Human gene therapy 2019; (30(5)):590-600 doi:10.1089/hum.2018.156.

    PMID: 30381971
  11. 11

    Dual AAV Vectors for Stargardt Disease.

    Trapani I

    Methods in molecular biology (Clifton, N.J.) 2018; (1715()):153-175 doi:10.1007/978-1-4939-7522-8_11.

    PMID: 29188512
  12. 12

    Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1).

    Li R, Jing Q, She K, et al.

    Human gene therapy 2023; (34(13-14)):616-628 doi:10.1089/hum.2023.017.

    PMID: 37227014
  13. 13

    Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients.

    Sung Y, Lee MJ, Choi J, et al.

    The British journal of ophthalmology 2021; (105(6)):829-837 doi:10.1136/bjophthalmol-2020-316225.

    PMID: 32727729
  14. 14

    Stem Cell Therapy in Stargardt Disease: A Systematic Review.

    Moghadam Fard A, Mirshahi R, Naseripour M, Ghasemi Falavarjani K

    Journal of ophthalmic & vision research 2023; (18(3)):318-327 doi:10.18502/jovr.v18i3.13780.

    PMID: 37600916
  15. 15

    Multimodal in-vivo maps as a tool to characterize retinal structural biomarkers for progression in adult-onset Stargardt disease.

    Pedersen HR, Gilson SJ, Hagen LA, et al.

    Frontiers in ophthalmology 2024; (4()):1384473 doi:10.3389/fopht.2024.1384473.

    PMID: 38984108
  16. 16

    Stargardt-like Clinical Characteristics and Disease Course Associated with Variants in the WDR19 Gene.

    Sajovic J, Meglič A, Volk M, et al.

    Genes 2023; (14(2)) doi:10.3390/genes14020291.

    PMID: 36833218
  17. 17

    Variants in the ABCA4 gene in a Brazilian population with Stargardt disease.

    Salles MV, Motta FL, Martin R, et al.

    Molecular vision 2018; (24()):546-559.

    PMID: 30093795
  18. 18

    Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients.

    Siles L, Ruiz-Nogales S, Navinés-Ferrer A, et al.

    Molecular therapy. Nucleic acids 2023; (32()):64-79 doi:10.1016/j.omtn.2023.02.032.

    PMID: 36969552
  19. 19

    Stargardt disease masquerades.

    Ricca AM, Han IC, Sohn EH

    Current opinion in ophthalmology 2021; (32(3)):214-224 doi:10.1097/ICU.0000000000000750.

    PMID: 33653979

This page provides information on current research and clinical trials for Stargardt disease for educational purposes only. It does not replace professional medical advice from your ophthalmologist or retina specialist.

Get notified when new evidence is published on Stargardt disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.